Search
PAVmed Inc
PAVMAdd to Watchlist
6.530USD
+0.040+0.62%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
46.75MMarket Cap
LossP/E TTM
More Details of PAVmed Inc Company
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
PAVmed Inc Info
Ticker SymbolPAVM
Company namePAVmed Inc
IPO dateJul 27, 2016
CEOAklog (Lishan)
Number of employees39
Security typeOrdinary Share
Fiscal year-endJul 27
Address360 Madison Avenue
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10017
Phone12129494319
Websitehttps://pavmed.com/
Ticker SymbolPAVM
IPO dateJul 27, 2016
CEOAklog (Lishan)
Company Executives of PAVmed Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
367.57K
+97.93%
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
21.65K
+64.33%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
21.10K
+66.03%
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
19.34K
+72.04%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Baxter
Mr. Timothy (Tim) Baxter
Independent Director
Independent Director
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
367.57K
+97.93%
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
21.65K
+64.33%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
21.10K
+66.03%
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
19.34K
+72.04%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tasso Partners, LLC
12.55%
Scopia Capital Management LP
8.66%
Nagelberg (David S)
7.52%
Kallman (Craig)
5.29%
Aklog (Lishan)
5.05%
Other
60.92%
Shareholders
Shareholders
Proportion
Tasso Partners, LLC
12.55%
Scopia Capital Management LP
8.66%
Nagelberg (David S)
7.52%
Kallman (Craig)
5.29%
Aklog (Lishan)
5.05%
Other
60.92%
Shareholder Types
Shareholders
Proportion
Individual Investor
30.19%
Corporation
12.69%
Hedge Fund
8.68%
Investment Advisor
1.13%
Investment Advisor/Hedge Fund
0.14%
Venture Capital
0.02%
Other
47.15%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
61
736.95K
10.13%
+659.92K
2025Q4
61
98.91K
9.93%
+37.00K
2025Q3
89
2.39M
8.50%
+565.99K
2025Q2
101
5.16M
29.26%
+2.76M
2025Q1
106
5.16M
31.74%
+3.03M
2024Q4
110
2.41M
17.67%
+156.53K
2024Q3
120
2.58M
24.42%
+197.13K
2024Q2
133
1.94M
20.61%
-301.78K
2024Q1
169
2.19M
26.52%
+433.78K
2023Q4
185
1.60M
20.86%
-48.73K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tasso Partners, LLC
85.81K
1.36%
+85.81K
--
Feb 21, 2025
Aklog (Lishan)
7.62K
0.12%
--
--
Feb 13, 2026
McGrath (Dennis M)
6.70K
0.11%
+1.00
+0.01%
Feb 13, 2026
O'Neil (Shaun)
5.60K
0.09%
--
--
Feb 13, 2026
Gordon (Michael Adam)
5.00K
0.08%
--
--
Feb 13, 2026
Sargent Investment Group, LLC
33.54K
0.53%
+33.54K
--
Jul 01, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Dec 30, 2025
Merger
30→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
Dec 30, 2025
Merger
30→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
